-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Nuochengjianhua (688428.SH) announced that the new-generation TRK inhibitor zolecutinib tablets (trade name: inoxin®) independently developed by the company were included in the new national medical insurance catalogue to treat adults carrying the NTRK fusion gene and patients with solid tumors in adolescents aged 12 and over. The new version of the National Health Insurance Catalogue will be officially implemented from January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.
Share
Listen to the news
Zhitong Finance App News, Nuochengjianhua (688428.SH) announced that the new-generation TRK inhibitor zolecutinib tablets (trade name: inoxin®) independently developed by the company were included in the new national medical insurance catalogue to treat adults carrying the NTRK fusion gene and patients with solid tumors in adolescents aged 12 and over. The new version of the National Health Insurance Catalogue will be officially implemented from January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending